Predict your next investment

Corporation
HEALTHCARE | Biotechnology
thermofisher.com

See what CB Insights has to offer

Investments

4

Portfolio Exits

6

Partners & Customers

10

About Thermo Fisher Scientific

Thermo Fisher Scientific provides a broad range of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics applications. Clients include pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions, and government agencies. The company's portfolio of products includes technologies for mass spectrometry, elemental analysis, molecular spectroscopy, sample preparation, informatics, fine and high-purity chemistry production, cell culture, RNA interference analysis, and immunodiagnostic testing.

Thermo Fisher Scientific Headquarter Location

168 Third Avenue

Waltham, Massachusetts, 02451,

United States

781 622 1000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Thermo Fisher Scientific

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Thermo Fisher Scientific in 6 Expert Collections, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

C

Cancer Liquid Biopsies

105 items

Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'

F

Fortune 500 Investor list

590 items

This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.

I

Infectious Disease

2,225 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

M

Medical Devices

3,425 items

https://mdic.org/membership/our-members/

H

Health Monitoring & Diagnostics

76 items

Companies developing companion diagnostics and technology enabling the development of companion diagnostics. Tagged as #CompanionDx

Thermo Fisher Scientific Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Thermo Fisher Scientific Rank

Research containing Thermo Fisher Scientific

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Thermo Fisher Scientific in 3 CB Insights research briefs, most recently on Mar 4, 2020.

Latest Thermo Fisher Scientific News

Bioprocess Technology Market Key Players, Industry Overview, Applications and Analysis 2031

Oct 22, 2021

Bioprocess Technology Market Key Players, Industry Overview, Applications and Analysis 2031 According to a recent study by Future Market Insights (FMI), the global  bioprocess technology market  was valued at US$ 17.3 Bn in 2020 and is expected to register a CAGR of 15.2% during the forecast period (2021-2031). It is projected to generate a revenue of US$ 81.2 Bn by the end of 2031. Technology has always been at the heart of biotech. The emergence of advanced computing technology such as machine learning and artificial intelligence has enabled companies to expand the scale of their research and improve efficiency in the manufacturing process—both of which reduce the time it takes for biotech firms to bring new products to market. Increasing research and development spending on pharmaceutical products has improved the well-being of patients to a significant level. Today vaccines have proven to be one of the most effective ways to prevent children from infectious diseases. This is highly possible due to increased government spending on research & development in the life science stream. To Get Sample Copy of Report visit @  https://www.futuremarketinsights.com/reports/sample/REP-GB-13890 For instance, in May 2020, AbSci Inc. closed USD 15.4 Mn in series D funding to accelerate the growth and scale of disruptive protein printing technology, by announcing an exclusive co-marketing partnership with KBI Biopharma. There are currently more than 1,500 biomolecules undergoing clinical trials, which target more than 100 hundred types of diseases and success rate for biologics has so far been over twice that of small-molecule products. Bioprocess Technology Market Key Takeaways from Bioprocess Technology Market Study In 2021, the BIOTECH/BIOPHARMACEUTICAL COMPANIES segment is expected to dominate the global bioprocess technology market with a 44.0% market share, whereas, CDMO/contract research organization segment is expected to occupy over 40% of the market share. By product, the upstream segment dominated the global Bioprocess Technology market with a 64.8% market share. Europe and East Asia dominated the global bioprocess technology market occupying over 24.3% and 14.7% market share, respectively. Who is winning? Some of the leading companies of bioprocess technology are focusing on their extensive portfolio of single-use cell culture bioreactors, containers, strong distribution channels, and strategic selling to the leading biopharmaceutical manufacturing entities. Thermo Fisher Scientific Inc. is a multinational biotech company that develops, manufactures, and distributes products in the areas of healthcare & diagnostics, life sciences, pharmaceuticals, and others. In Sep 2020, Thermo Fisher Scientific Inc. announced the opening of its new Bioprocessing Collaboration Center (BCC) in St. Louis, Missouri. Sartorius AG is a leading provider of contract testing services to the global biotechnology and biopharmaceutical industries. In July 2020, Sartorius Stedim Biotech acquired a majority stake in CellGenix to strengthen its product portfolio for cell and gene therapies. Danaher Corporation designs manufacture and markets professional, medical, industrial, and commercial products and services. In March 2020 Danaher Corporation acquired the Biopharma business from General Electric’s Life Sciences division. The key market players covered by FMI include Thermo Fisher Scientific Inc, Sartorius, Merck KGa, Danaher Corporation, Applikon Biotechnology B.V., Lonza AG, Bio-Rad Laboratories, Agilent technologies, Solida Biotech GmBH, and Waters Corporation. Ask an Analyst @  https://www.futuremarketinsights.com/ask-question/rep-gb-13890 · Detailed insights of market segments and sub-segments for historical as well as forecast period · A competitive analysis of prominent players and emerging players in the keyword market · Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario About FMI: Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers. Contact Us:

Thermo Fisher Scientific Investments

4 Investments

Thermo Fisher Scientific has made 4 investments. Their latest investment was in WuXi Diagnostics as part of their Series B on February 2, 2021.

CBI Logo

Thermo Fisher Scientific Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/24/2021

Series B

WuXi Diagnostics

$150M

Yes

9

10/30/2019

Series A

Subscribe to see more

$99M

Subscribe to see more

10

2/19/2019

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

3/11/2004

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/24/2021

10/30/2019

2/19/2019

3/11/2004

Round

Series B

Series A

Corporate Minority

Series A

Company

WuXi Diagnostics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$150M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

9

10

10

10

Thermo Fisher Scientific Portfolio Exits

6 Portfolio Exits

Thermo Fisher Scientific has 6 portfolio exits. Their latest portfolio exit was Epredia on June 29, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/29/2019

Divestiture

1

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

6/29/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Exit

Divestiture

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Thermo Fisher Scientific Acquisitions

41 Acquisitions

Thermo Fisher Scientific acquired 41 companies. Their latest acquisition was PPD on April 15, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

4/15/2021

IPO - II

$991

$71.05M

Acq - Pending

13

2/17/2021

Acquired Unit

1

1/19/2021

Grant - II

$991

$41.48M

Acquired

20

1/15/2021

Subscribe to see more

$991

$99M

Subscribe to see more

10

1/15/2021

Subscribe to see more

$991

$99M

Subscribe to see more

10

Date

4/15/2021

2/17/2021

1/19/2021

1/15/2021

1/15/2021

Investment Stage

IPO - II

Grant - II

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

Total Funding

$71.05M

$41.48M

$99M

$99M

Note

Acq - Pending

Acquired Unit

Acquired

Subscribe to see more

Subscribe to see more

Sources

13

1

20

10

10

Thermo Fisher Scientific Partners & Customers

10 Partners and customers

Thermo Fisher Scientific has 10 strategic partners and customers. Thermo Fisher Scientific recently partnered with StemExpress on October 10, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

10/5/2021

Client

StemExpress

United States

15:33 ET StemExpress Partners with the Alliance for Regenerative Medicine to Provide COVID-19 Testing for the Cell and Gene Meet...

The StemExpress partnership with Alliance seeks to empower the entire cell and gene industry with a long-awaited opportunity to return to traditional networking practices .

2

8/4/2021

Client

Oncolys BioPharma

Japan

1

7/21/2021

Partner

Berkeley Lights

United States

Berkeley Lights announces technology collaboration to accelerate and improve gene therapy viral vector development and manufacturing

The partnership , which began in December of 2020 , brings together Berkeley Lights , Inc. ' leadership in functional biology characterization with Thermo Fisher Scientific 's expertise in viral vector manufacturing and analytics .

1

7/13/2021

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

7/7/2021

Licensee

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

10/5/2021

8/4/2021

7/21/2021

7/13/2021

7/7/2021

Type

Client

Client

Partner

Partner

Licensee

Business Partner

StemExpress

Oncolys BioPharma

Berkeley Lights

Country

United States

Japan

United States

Subscribe to see more

Subscribe to see more

News Snippet

15:33 ET StemExpress Partners with the Alliance for Regenerative Medicine to Provide COVID-19 Testing for the Cell and Gene Meet...

The StemExpress partnership with Alliance seeks to empower the entire cell and gene industry with a long-awaited opportunity to return to traditional networking practices .

Berkeley Lights announces technology collaboration to accelerate and improve gene therapy viral vector development and manufacturing

The partnership , which began in December of 2020 , brings together Berkeley Lights , Inc. ' leadership in functional biology characterization with Thermo Fisher Scientific 's expertise in viral vector manufacturing and analytics .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

1

1

10

10

Thermo Fisher Scientific Team

45 Team Members

Thermo Fisher Scientific has 45 team members, including current Chief Executive Officer, President, Marc Casper.

Name

Work History

Title

Status

Marc Casper

Chief Executive Officer, President

Current

Daniella Cramp

President, Senior Vice President

Current

Greg Herrema

President, Senior Vice President

Current

Syed Jafry

President, Senior Vice President

Current

Peter Silvester

President, Senior Vice President

Current

Name

Marc Casper

Daniella Cramp

Greg Herrema

Syed Jafry

Peter Silvester

Work History

Title

Chief Executive Officer, President

President, Senior Vice President

President, Senior Vice President

President, Senior Vice President

President, Senior Vice President

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.